Clinical Trial

A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-16.
Trial Details
NCT Number NCT07717775
Lead Sponsor Addpharma Inc.
Conditions Gastritis
Enrollment 30 participants
Start Date 2026-08
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-27